Article Information
History
- December 22, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Raches Ella, MBBS, MS1,*,
- Siddharth Reddy, MSc1,
- Harsh Jogdand, PhD1,
- Vamshi Sarangi, BSc1,
- Brunda Ganneru, PhD1,
- Sai Prasad, MBA1,
- Dipankar Das, PhD1,
- Dugyala Raju, PhD1,
- Usha Praturi, MSc1,
- Gajanan Sapkal, PhD2,
- Pragya Yadav, PhD2,
- Prabhakar Reddy, MD4,
- Savita Verma, MD5,
- Chandramani Singh, MD6,
- Sagar Vivek Redkar, MD7,
- Chandra Sekhar Gillurkar, MD8,
- Jitendra Singh Kushwaha, MD9,
- Satyajit Mohapatra, MD10,
- Amit Bhate, MD11,
- Sanjay Rai, MD12,
- Samiran Panda, MD3,
- Priya Abraham, PhD2,
- Nivedita Gupta, MD3,
- Krishna Ella, PhD1,
- Balram Bhargava, MD3 and
- Krishna Mohan Vadrevu, PhD1
- 1Bharat Biotech, Hyderabad, India
- 2Indian Council of Medical Research-National Institute of Virology, Pune, India
- 3Indian Council of Medical Research, New Delhi, India
- 4Nizams Institute of Medical Sciences, Hyderabad, India
- 5Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India
- 6All India Institute of Medical Sciences, Patna, India
- 7Redkar Hospital, Dargalim, India
- 8Gillurkar Hospital, Nagpur, India
- 9Prakhar Hospital, Kanpur, India
- 10SRM Hospital and Research Centre, Kattankulathur, India
- 11Jeevan Rekha Hospital, Belgaum, India
- 12All India Institute of Medical Sciences, New Delhi, India
- ↵* Corresponding author; email: rachesella{at}gmail.com
Posted December 22, 2020.
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report
